

MTN 023 - Study of Dapivirine Vaginal Ring (VR) in Adolescents
Report Generation Date: June 7, 2022
Visit Cutoff Date: March 9, 2017¹
Retention by Visit and Site

	Birmingham, AL	Bronx, NY	Denver, CO	Fenway, MA	Memphis, TN	Pittsburgh, PA	All Sites
Participants Enrolled	9	16	23	10	18	20	96
1-Week Follow-up Phone Call							
Expected ²	9	16	23	10	18	20	96
Completed ³	9 (100%)	16 (100%)	22 (96%)	10 (100%)	17 (94%)	20 (100%)	94 (98%)
Not Completed	0 (0%)	0 (0%)	1 (4%)	0 (0%)	1 (6%)	0 (0%)	2 (2%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (6%)	0 (0%)	1 (1%)
Terminated Early	0 (0%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Not Expected	0	0	0	0	0	0	0
2-Week Visit							
Expected ²	9	16	23	10	18	20	96
Completed ³	9 (100%)	16 (100%)	22 (96%)	8 (80%)	17 (94%)	20 (100%)	92 (96%)
Not Completed	0 (0%)	0 (0%)	1 (4%)	2 (20%)	1 (6%)	0 (0%)	4 (4%)
Missed	0 (0%)	0 (0%)	0 (0%)	2 (20%)	1 (6%)	0 (0%)	3 (3%)
Terminated Early	0 (0%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Not Expected	0	0	0	0	0	0	0
4-Week Visit							
Expected ²	9	16	23	10	18	20	96
Completed ³	9 (100%)	16 (100%)	22 (96%)	8 (80%)	18 (100%)	20 (100%)	93 (97%)
Not Completed	0 (0%)	0 (0%)	1 (4%)	2 (20%)	0 (0%)	0 (0%)	3 (3%)
Missed	0 (0%)	0 (0%)	0 (0%)	2 (20%)	0 (0%)	0 (0%)	2 (2%)
Terminated Early	0 (0%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Not Expected	0	0	0	0	0	0	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

MTN 023 - Study of Dapivirine Vaginal Ring (VR) in Adolescents
Report Generation Date: June 7, 2022
Visit Cutoff Date: March 9, 2017¹
Retention by Visit and Site

	Birmingham, AL	Bronx, NY	Denver, CO	Fenway, MA	Memphis, TN	Pittsburgh, PA	All Sites
8-Week Visit							
Expected ²	9	16	23	10	18	20	96
Completed ³	9 (100%)	14 (88%)	22 (96%)	9 (90%)	18 (100%)	19 (95%)	91 (95%)
Not Completed	0 (0%)	2 (13%)	1 (4%)	1 (10%)	0 (0%)	1 (5%)	5 (5%)
Missed	0 (0%)	2 (13%)	0 (0%)	1 (10%)	0 (0%)	1 (5%)	4 (4%)
Terminated Early	0 (0%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Not Expected	0	0	0	0	0	0	0
12-Week/Final Clinic Visit							
Expected ²	9	16	23	10	18	20	96
Completed ³	8 (89%)	14 (88%)	21 (91%)	8 (80%)	17 (94%)	19 (95%)	87 (91%)
Not Completed	1 (11%)	2 (13%)	2 (9%)	2 (20%)	1 (6%)	1 (5%)	9 (9%)
Missed	1 (11%)	2 (13%)	1 (4%)	2 (20%)	1 (6%)	1 (5%)	8 (8%)
Terminated Early	0 (0%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Not Expected	0	0	0	0	0	0	0
13-Week Follow-up Phone Call							
Expected ²	2	2	4	3	0	0	11
Completed ³	2 (100%)	2 (100%)	4 (100%)	3 (100%)	0 (0%)	0 (0%)	11 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0	0	0	0	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

MTN 023 - Study of Dapivirine Vaginal Ring (VR) in Adolescents
Report Generation Date: June 7, 2022
Visit Cutoff Date: March 9, 2017¹
Retention by Visit and Site

	Birmingham, AL	Bronx, NY	Denver, CO	Fenway, MA	Memphis, TN	Pittsburgh, PA	All Sites
16-Week Visit							
Expected ²	7	14	19	7	18	20	85
Completed ³	6 (86%)	12 (86%)	17 (89%)	7 (100%)	17 (94%)	19 (95%)	78 (92%)
Not Completed	1 (14%)	2 (14%)	2 (11%)	0 (0%)	1 (6%)	1 (5%)	7 (8%)
Missed	0 (0%)	1 (7%)	1 (5%)	0 (0%)	1 (6%)	1 (5%)	4 (5%)
Terminated Early	1 (14%)	1 (7%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	3 (4%)
Not Expected	0	0	0	0	0	0	0
20-Week Visit							
Expected ²	7	14	19	7	18	20	85
Completed ³	5 (71%)	13 (93%)	16 (84%)	6 (86%)	17 (94%)	19 (95%)	76 (89%)
Not Completed	2 (29%)	1 (7%)	3 (16%)	1 (14%)	1 (6%)	1 (5%)	9 (11%)
Missed	1 (14%)	0 (0%)	2 (11%)	1 (14%)	0 (0%)	0 (0%)	4 (5%)
Terminated Early	1 (14%)	1 (7%)	1 (5%)	0 (0%)	1 (6%)	1 (5%)	5 (6%)
Not Expected	0	0	0	0	0	0	0
24-Week Visit							
Expected ²	7	14	19	7	18	20	85
Completed ³	6 (86%)	13 (93%)	17 (89%)	7 (100%)	17 (94%)	19 (95%)	79 (93%)
Not Completed	1 (14%)	1 (7%)	2 (11%)	0 (0%)	1 (6%)	1 (5%)	6 (7%)
Missed	0 (0%)	0 (0%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Terminated Early	1 (14%)	1 (7%)	1 (5%)	0 (0%)	1 (6%)	1 (5%)	5 (6%)
Not Expected	0	0	0	0	0	0	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

MTN 023 - Study of Dapivirine Vaginal Ring (VR) in Adolescents
Report Generation Date: June 7, 2022
Visit Cutoff Date: March 9, 2017¹
Retention by Visit and Site

	Birmingham, AL	Bronx, NY	Denver, CO	Fenway, MA	Memphis, TN	Pittsburgh, PA	All Sites
25-Week Follow-up Phone Call							
Expected ²	7	14	19	7	18	20	85
Completed ³	6 (86%)	13 (93%)	18 (95%)	7 (100%)	17 (94%)	19 (95%)	80 (94%)
Not Completed	1 (14%)	1 (7%)	1 (5%)	0 (0%)	1 (6%)	1 (5%)	5 (6%)
Missed	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Terminated Early	1 (14%)	1 (7%)	1 (5%)	0 (0%)	1 (6%)	1 (5%)	5 (6%)
Not Expected	0	0	0	0	0	0	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.